Equities analysts expect Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) to post earnings of ($0.67) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Trillium Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.78) and the highest estimate coming in at ($0.55). Trillium Therapeutics posted earnings of ($0.84) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 20.2%. The firm is expected to issue its next earnings report on Friday, November 9th.
According to Zacks, analysts expect that Trillium Therapeutics will report full year earnings of ($2.49) per share for the current financial year, with EPS estimates ranging from ($2.60) to ($2.34). For the next year, analysts expect that the company will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.53) to ($1.79). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Trillium Therapeutics.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.05).
Several hedge funds and other institutional investors have recently modified their holdings of TRIL. Stanley Laman Group Ltd. raised its holdings in shares of Trillium Therapeutics by 26.7% in the second quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock worth $823,000 after buying an additional 28,907 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Trillium Therapeutics by 245.3% in the second quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock worth $864,000 after buying an additional 102,300 shares during the period. Baker BROS. Advisors LP raised its holdings in shares of Trillium Therapeutics by 25.0% in the second quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock worth $3,071,000 after buying an additional 102,440 shares during the period. Finally, Wealth Alliance Advisory Group LLC purchased a new stake in shares of Trillium Therapeutics in the third quarter worth approximately $126,000. Hedge funds and other institutional investors own 48.77% of the company’s stock.
NASDAQ:TRIL opened at $3.34 on Friday. The company has a market capitalization of $47.01 million, a PE ratio of -0.94 and a beta of 2.40. Trillium Therapeutics has a 1 year low of $2.83 and a 1 year high of $13.30.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Story: Stock Symbols and CUSIP Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.